- Home
- DAVA vs NVAX Comparison
DAVA vs NVAX Comparison
Compare DAVA & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAVA
- NVAX
- Stock Information
- Founded
- DAVA 2000
- NVAX 1987
- Country
- DAVA United Kingdom
- NVAX United States
- Employees
- DAVA N/A
- NVAX N/A
- Industry
- DAVA EDP Services
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DAVA Technology
- NVAX Health Care
- Exchange
- DAVA Nasdaq
- NVAX Nasdaq
- Market Cap
- DAVA 1.2B
- NVAX 1.3B
- IPO Year
- DAVA 2018
- NVAX 1995
- Fundamental
- Price
- DAVA $14.78
- NVAX $6.29
- Analyst Decision
- DAVA Buy
- NVAX Buy
- Analyst Count
- DAVA 10
- NVAX 6
- Target Price
- DAVA $35.31
- NVAX $17.50
- AVG Volume (30 Days)
- DAVA 1.0M
- NVAX 9.0M
- Earning Date
- DAVA 05-14-2025
- NVAX 05-08-2025
- Dividend Yield
- DAVA N/A
- NVAX N/A
- EPS Growth
- DAVA N/A
- NVAX N/A
- EPS
- DAVA 0.40
- NVAX 2.97
- Revenue
- DAVA $1,007,631,882.00
- NVAX $1,254,962,000.00
- Revenue This Year
- DAVA $9.20
- NVAX N/A
- Revenue Next Year
- DAVA $6.60
- NVAX N/A
- P/E Ratio
- DAVA $39.32
- NVAX $2.12
- Revenue Growth
- DAVA 5.95
- NVAX 25.92
- 52 Week Low
- DAVA $16.60
- NVAX $4.43
- 52 Week High
- DAVA $34.94
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- DAVA 31.80
- NVAX 48.26
- Support Level
- DAVA $18.50
- NVAX $5.87
- Resistance Level
- DAVA $21.81
- NVAX $6.46
- Average True Range (ATR)
- DAVA 1.00
- NVAX 0.47
- MACD
- DAVA -0.15
- NVAX 0.01
- Stochastic Oscillator
- DAVA 6.08
- NVAX 28.82
About DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the U.K. and it continues to generate the majority of revenue in the U.K. and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.